Leerink Partnrs Estimates XOMA’s Q1 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – Leerink Partnrs issued their Q1 2025 earnings estimates for shares of XOMA in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will post earnings of ($0.31) per share for the quarter. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.00 EPS and FY2029 earnings at $8.86 EPS.

XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%.

XOMA has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $104.00 price target on shares of XOMA in a research note on Wednesday. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Stock Performance

NASDAQ XOMA opened at $20.90 on Wednesday. XOMA has a 52-week low of $19.92 and a 52-week high of $35.00. The company has a fifty day moving average of $24.55 and a 200-day moving average of $27.24. The company has a market capitalization of $246.26 million, a P/E ratio of -6.01 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.20% of the stock is owned by corporate insiders.

Institutional Trading of XOMA

Several hedge funds and other institutional investors have recently bought and sold shares of XOMA. BNP Paribas Financial Markets increased its stake in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares during the period. New York State Common Retirement Fund increased its position in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 800 shares during the period. Wells Fargo & Company MN raised its stake in shares of XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,183 shares during the last quarter. Bank of America Corp DE raised its stake in shares of XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,009 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of XOMA during the fourth quarter worth about $206,000. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.